Patricia LoRusso
帕特里夏·洛鲁索
DO, FACP
Professor of Medicine (Medical Oncology); Associate Director for Innovative Medicine, Yale Cancer Center; Leader, Developmental Therapeutics Research Program医学教授（医学肿瘤学）；耶鲁癌症中心创新医学副主任；开发性治疗研究项目负责人
👥Biography 个人简介
Patricia LoRusso, DO, FACP is Professor of Medicine (Medical Oncology) and Associate Director for Innovative Medicine at Yale Cancer Center, and leads the Developmental Therapeutics Research Program at Yale School of Medicine. Dr. LoRusso is one of the most experienced phase I oncologists in the United States, with a career spanning over three decades of first-in-human and early-phase drug development. Before joining Yale, she directed the Oncology Phase I Program at Barbara Ann Karmanos Cancer Institute in Detroit for many years, building one of the most productive academic phase I programs in the country. Dr. LoRusso's primary scientific interest and clinical expertise lies in antibody-based cancer therapies, having led first-in-human trials of numerous monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, and antibody-based immune engagers across solid tumor histologies. She has been a principal investigator on first-in-human trials of multiple ADC platforms targeting HER2, EGFR, TROP2, HER3, Nectin-4, and B7-H3, contributing foundational pharmacokinetic/pharmacodynamic data that informed registrational trial design. Dr. LoRusso is a past president of both the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC), and has served on multiple FDA advisory committees. She is a founding leader of the AACR's phase I oncology education and training initiative and a mentor to an entire generation of developmental therapeutics oncologists.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Antibody-Drug Conjugate First-in-Human Phase I Development
Led first-in-human phase I trials of multiple ADC platforms including early-generation anti-HER2 ADCs (including studies contributing to ado-trastuzumab emtansine [T-DM1] development), EGFR-targeting ADCs, and subsequent generations of topoisomerase I payload-based conjugates (DXd-linker platform). Characterized the mechanism-based toxicity profiles unique to ADCs — including thrombocytopenia, neutropenia, peripheral neuropathy, and interstitial lung disease — and developed the pharmacokinetic models relating total antibody, conjugated antibody, and free payload exposure to both efficacy and adverse event risk, establishing frameworks still used in ADC clinical development today.
Bispecific Antibody First-in-Human Trials — CD3-Engaging Immune Engagers
Pioneered first-in-human clinical development of multiple bispecific T-cell engager (BiTE) and IgG-based bispecific antibody formats targeting tumor antigens (EpCAM, HER2, PSMA, EGFR) in combination with CD3 or CD28 on T cells. Characterized cytokine release syndrome (CRS) as the primary dose-limiting toxicity of CD3-bispecifics in solid tumors, established step-up dosing and hospitalization protocols to mitigate CRS, and conducted tumor biopsies demonstrating T-cell infiltration and pharmacodynamic activation as proof-of-mechanism biomarkers.
EGFR and HER2 Targeting — Phase I Mechanistic and Combination Studies
Conducted extensive phase I development of EGFR and HER2 pathway-targeted agents across solid tumor histologies including colorectal, lung, head and neck, and breast cancers. Led combination phase I trials pairing EGFR/HER2 inhibitors with DNA-damaging agents, PI3K pathway inhibitors, and checkpoint inhibitors, defining pharmacodynamic biomarkers (pEGFR, pAKT, pERK in tumor biopsies) and dose optimization strategies that advanced multiple agents into phase II and III development.
Phase I Program Leadership and National Training in Developmental Therapeutics
Built and directed major academic phase I programs at Karmanos Cancer Institute and then Yale Cancer Center, developing institutional infrastructure for molecular prescreening, pharmacokinetic sampling, mandatory tumor biopsies, and adverse event management in first-in-human trials. As ASCO and SITC president, championed phase I-specific education curriculum in fellowship training, authored consensus guidelines on biologic agent safety monitoring, and established mentorship programs in developmental therapeutics that have trained hundreds of academic oncologists across North America.
Representative Works 代表性著作
Phase I Study of Trastuzumab Emtansine (T-DM1), a HER2 Antibody-Drug Conjugate, in Patients with Advanced HER2-Positive Breast Cancer
Clinical Cancer Research (2011)
Pivotal phase I characterization of T-DM1 pharmacokinetics, safety, and early efficacy signals in HER2-positive breast cancer, establishing the foundation for the EMILIA phase III trial and FDA approval.
A Phase I Study of the Safety, Pharmacokinetics, and Antitumor Activity of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Receptor Type 1
Clinical Cancer Research (2011)
First-in-human phase I of ganitumab (AMG 479) characterizing IGF-1R inhibition pharmacodynamics and identifying hyperglycemia as a class-based pharmacodynamic biomarker of target engagement.
First-in-Human Phase I Study of the PARP Inhibitor Niraparib in Patients with Advanced Solid Tumors
Clinical Cancer Research (2013)
First-in-human phase I characterization of niraparib safety, pharmacokinetics, and pharmacodynamics (PAR inhibition in PBMCs and tumor biopsies) establishing dose and schedule for subsequent BRCA-enriched phase III trials.
Antibody-Drug Conjugates: An Emerging Class of Cancer Treatment
Journal of Clinical Oncology (2018)
Comprehensive review of ADC clinical development principles including linker chemistry, payload selection, resistance mechanisms, and phase I toxicity management frameworks based on decades of first-in-human trial experience.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 帕特里夏·洛鲁索 的研究动态
Follow Patricia LoRusso's research updates
留下邮箱，当我们发布与 Patricia LoRusso（Yale School of Medicine; Yale Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment